QUALITY CONTROL PARAMETERS OF VATARI GUGGULU- AN AYURVEDIC FORMULATION

Vatari Guggulu has been prepared according to Bhaishajya Ratnavali and is indicated in Amavata, Gridhrasi, Katishula etc. It is an example of Guggulu kalpa in Vati form which means medicines containing equal or more amount of Guggulu as compared to amount of other ingredients. Vatari Guggulu is prepared from Castor oil, Gandhaka (Processed Sulphur), Triphala (Haritaki, Bibhitaki and Amalaki) and Guggulu. The present study deals with development of pharmacognostical and preliminary pharmaceutico-analytical profile of Vatari Guggulu which is lacking. It revealed the pH [5% aqueous suspension] is 4.0, water-soluble extractive 29.1% w/w, alcohol-soluble extractive 41.84% w/w, carbon di sulphide extractive 22.76% w/w, petroleum ether soluble extractive 15.48% w/w, ash value 14.77% w/w and loss on drying [at 105°C] are 8.35%w/w. Physical tests revealed average weight of Vatari Guggulu vati is 376 mg and 7.51 mm diameter and has an average 2.18 kg/cm2 hardness, disintegration time 2 hr 45 min [in distilled water] and 0.00043% friability. High performance thin layer chromatography [HPTLC] of alcoholic extract of drug revealed 6 and 5 Rf values at 256 and 366 nm out of which only one Rf was similar among Rf values at either wavelength.

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362